Ginkgo Bioworks Holdings, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

In September 2021, Ginkgo Bioworks went public by way of a deSPAC transaction with blank check company Soaring Eagle Acquisition Corporation. Scorpion Capital, a short seller, released a report on October 6, 2021, stating Ginkgo Bioworks is a “colossal scam.” Scorpion says within this report that, “We believe that Ginkgo is concealing the true extent of its dependence on related party revenue and that it is even greater than it reports. We have uncovered a smoking gun that indicates that essentially all of its foundry revenue is derived from related parties.” On October 6, 2021, Ginkgo Bioworks’ stock price fell over 20% in early morning trading, following this news